Canakinumab adjuvant therapy for treating completely
resected non-small-cell lung cancer

Canakinumab is in clinical development as an adjuvant therapy for stage II-III non-small cell lung
cancer (NSCLC) that has been surgically completely removed. NSCLC accounts for most lung
cancers that are diagnosed and can originate anywhere in the lungs but may spread to surrounding
tissues as the disease progresses. Adjuvant therapy is a treatment given after the primary
treatment, which in II-III stage NSCLC is often the complete surgical removal of the cancer. The
risk of recurrence/relapse without additional adjuvant therapy remains high, as some cancer cells
may have been left behind.